Bailard, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Bailard, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $213,520 - $474,912	-6,800 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$40.9 - $64.9 $245,400 - $389,400	-6,000 Reduced 46.88%	6,800 $430,000
Q1 2021 May 13, 2021	SELL	$40.8 - $57.39 $48,960 - $68,868	-1,200 Reduced 8.57%	12,800 $549,000
Q4 2020 Feb 03, 2021	SELL	$30.79 - $57.2 $89,291 - $165,880	-2,900 Reduced 17.16%	14,000 $801,000
Q2 2020 Aug 12, 2020	BUY	$24.8 - $38.49 $124,000 - $192,450	5,000 Added 42.02%	16,900 $552,000
Q1 2020 Apr 16, 2020	BUY	$17.91 - $44.33 $16,119 - $39,897	900 Added 8.18%	11,900 $319,000
Q4 2019 Jan 31, 2020	SELL	$22.1 - $30.8 $88,400 - $123,200	-4,000 Reduced 26.67%	11,000 $337,000
Q2 2019 Jul 26, 2019	BUY	$18.0 - $25.34 $36,000 - $50,680	2,000 Added 15.38%	15,000 $380,000
Q1 2019 Apr 24, 2019	BUY	$12.81 - $19.82 $166,530 - $257,660	13,000 New	13,000 $254,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.